In this longitudinal ctDNA analysis of patients with metastatic hormone receptor -positive/HER2-negative BC during first-line ETx, we reported the prevalence and trajectory of ESR1 mutations and analyzed their correlation with clinical course and PFS. The gene discussed is ERBB2; the disease is breast cancer.